Be the first person to write a business review for Agencourt Bioscience Corporation

Agennix develops oral, topical, and other forms of cancer treatments. The company's primary candidate, Talactoferrin, is an oral therapy in the late stages of development that is targeted to treat non-small cell lung cancer, a common and slow-growing type of lung cancer. Its other clinical development-stage candidates include therapies to treat tumors and prostate cancer, as well as non-cancerous conditions such as sepsis and diabetic foot ulcers. Agennix, which has offices in Munich, Germany; Princeton, New Jersey; and Houston, Texas, was formed in 2009 from the merger of Germany-based GPC Biotech AG and US-based Agennix Inc.

Aldagen's work stems from the need for tissue repair. The biopharmaceutical company develops cell regeneration therapies using adult stem cells. It uses a proprietary technology that isolates an enzyme known as aldehyde dehydrogenase, or ALDH, which it believes can target a number of diseases. Aldagen hopes its products will be used to treat hereditary metabolic diseases in children, leukemia, and cardiovascular diseases; all its drugs are in the development stage. The company does its own manufacturing and plans to do its own marketing. Venture capital firm Intersouth Partners holds about 42% of Aldagen, which filed an IPO in late 2009. The company is led by CEO W. Thomas Amick.

Alfacell Corporation was founded in 1981 and is headquartered in Somerset, New Jersey. Alfacell Corporation, a biopharmaceutical company, primarily engages in the discovery and development of a class of therapeutic drugs for the treatment of cancer and other pathological conditions. Its proprietary drug discovery and development program consists of therapeutics developed from amphibian ribonucleases. The company's lead drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. It also focuses on new drug application for unresectable malignant mesothelioma. In addition, the company completed a Phase I clinical trial for the treatment of non-small cell lung cancer.

Alimera Sciences' tunnel vision is a real asset. The biopharmaceutical company specializes in prescription ophthalmic pharmaceuticals, particularly those aimed at treating ocular diseases affecting the retina. Alimera's most advanced product candidate, Iluvien, is an insert about the size of a grain of rice that slowly releases a drug to the back of the eye used in the treatment of diabetic macular edema (DME); DME, a retinal disease affecting diabetics, can lead to severe vision loss and blindness. Iluvien is effective for up to 36 months and may also have the potential to affect other ophthalmic diseases, such as retinal vein occlusion (RVO). Alimera Sciences is looking to go public through an $80 million IPO.

Alizyme is fighting the good fight against ills brought on by the good life. The development-stage biotechnology company licenses drug candidates and develops them. It targets conditions prevalent primarily in industrialized countries, including obesity, type 2 diabetes (often associated with obesity), and ulcerative colitis. Alizyme is focused on developing a family of lipase inhibitors, which prevent the body from absorbing fat. In addition to its pipeline of treatments for lifestyle-related conditions, the company is developing a drug for mucositis, cancer therapy-induced damage to the gastrointestinal tract.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.